文献速递肝病

PNPLA3 rs738409 C>G 变异通过无创工具预测非酒精性脂肪性肝病的纤维化进展

PNPLA3 rs738409 C>G Variant Predicts Fibrosis Progression by Noninvasive Tools in Nonalcoholic Fatty Liver Disease.
PubMed 文献 · Clin Gastroenterol Hepatol · 2020-09-06

研究旨在评估非酒精性脂肪性肝病(NAFLD)患者中 PNPLA3 rs738409 C>G 变异是否影响通过 FIB-4 和肝脏硬度测量(LSM)无创评估的纤维化进展。原文未报告具体研究设计与样本量,未报告主要结论或指南推荐。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Liver fibrosis is the main predictor of events in patients with nonalcoholic fatty liver disease (NAFLD),1 and its evolution is characterized by a nonlinear trend2,3 mostly affected by metabolic risk factors, severity of liver inflammation and steatosis, and weight loss.3 The rs738409 C>G common variant in PNPLA3 gene has been associated with severity of fibrosis and risk of liver-related events in NAFLD.4,5 Noninvasive tests as Fibrosis-4 (FIB-4) and liver stiffness measurement (LSM) are useful to rule-out advanced fibrosis and they could be reliable to predict fibrosis progression.2,6 We aimed to evaluate in patients with NAFLD whether PNPLA3 rs738409 C>G variant impacts on fibrosis progression, noninvasively assessed by FIB-4 and LSM.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Pennisi G, Pipitone RM, Cammà C, et al. PNPLA3 rs738409 C>G Variant Predicts Fibrosis Progression by Noninvasive Tools in Nonalcoholic Fatty Liver Disease. Clin Gastroenterol Hepatol. 2020. PMID: 32898706. doi:10.1016/j.cgh.2020.09.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。